본문으로 건너뛰기
← 뒤로

Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence.

1/5 보강
Head & neck 📖 저널 OA 38.3% 2021: 4/19 OA 2022: 2/25 OA 2023: 15/31 OA 2024: 30/52 OA 2025: 32/60 OA 2026: 25/65 OA 2021~2026 2025 Vol.47(12) p. 3285-3293
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: DTC treated with adjuvant Intensity Modulated radiotherapy (IMRT) from 2011 to 2024
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Late toxicity, including tracheostomy placement and feeding tube dependence, was seen in three and one patient, respectively. [CONCLUSION] Adjuvant IMRT in patients with DTC with high risk of locoregional recurrence resulted in good LRC with acceptable toxicities.

Laskar SG, Mohanty S, Sinha S, Kumar A, Pantvaidya G, Thiagarajan S, Budrukkar A, Swain M, Deshmukh A, Nair D, Vaish R, Tuljapurkar V, Dravid C, Nair S, Joshi P, Shetty R, Singh AG, Chaturvedi P

📝 환자 설명용 한 줄

[INTRODUCTION] There is limited evidence on the role of adjuvant external beam radiotherapy in differentiated thyroid cancer (DTC).

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 추적기간 53 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Laskar SG, Mohanty S, et al. (2025). Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence.. Head & neck, 47(12), 3285-3293. https://doi.org/10.1002/hed.28222
MLA Laskar SG, et al.. "Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence.." Head & neck, vol. 47, no. 12, 2025, pp. 3285-3293.
PMID 40662300 ↗
DOI 10.1002/hed.28222

Abstract

[INTRODUCTION] There is limited evidence on the role of adjuvant external beam radiotherapy in differentiated thyroid cancer (DTC).

[METHODS] We conducted a retrospective study of patients with DTC treated with adjuvant Intensity Modulated radiotherapy (IMRT) from 2011 to 2024.

[RESULTS] Fifty-nine patients were analyzed with median follow-up of 53 months. All the patients had undergone total thyroidectomy. Gross extrathyroidal extension was seen in 76% of patients, while 54% had R1/R2 resection. High-risk histological types were seen in 51% of patients, while 34% had recurrent disease. The 5-year locoregional control (LRC) was 89.3% while 5-year overall survival (OS) was 84.6%. Acute Grade 3 dermatitis and dysphagia were seen in 12% and 10%, respectively. Late toxicity, including tracheostomy placement and feeding tube dependence, was seen in three and one patient, respectively.

[CONCLUSION] Adjuvant IMRT in patients with DTC with high risk of locoregional recurrence resulted in good LRC with acceptable toxicities.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기